Antibiotic Use and Bacterial Infection in COVID-19 Patients in the Second Phase of the SARS-CoV-2 Pandemic: A Scoping Review.
Antibiotic Use and Bacterial Infection in COVID-19 Patients in the Second Phase of the SARS-CoV-2 Pandemic: A Scoping Review.
复制标题
DOI：
10.3390/antibiotics11080991
复制
发表时间：
2022-07-23
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
该范围审查旨在从2020年6月至2021年3月期间发表的研究中探索全球抗生素使用和2019冠状病毒病患者细菌感染的患病率和模式。本综述的报告符合系统性综述和荟萃分析的首选报告（PRISMA）范围综述扩展，并且该方案已在开放科学框架中注册。与我们之前发表的对这一时期的回顾相比，（2019年12月至2020年6月），新冠肺炎患者的抗生素处方率（2020年6月至2021年3月）整体下降（82.3% vs. 39.7%），轻度和中度患者（75.1% vs. 15.5%），重度和危重患者（75.3% vs. 48.3%）。COVID-19患者最常处方的七种抗生素均在WHO AWaRe抗生素分类的“观察”名单上。COVID-19患者的总体报告细菌感染率为10.5%，COVID-19患者中最常报告的耐药病原体为金黄色葡萄球菌，其次为铜绿假单胞菌、大肠埃希菌和肺炎克雷伯菌。迫切需要建立全面一致的指南，以帮助临床医生在需要时为COVID-19患者选择合适的抗生素。应密切监测COVID-19患者最常用抗生素对某些耐药病原体的耐药性数据。
This scoping review aimed to explore the prevalence and patterns of global antibiotic use and bacterial infection in COVID-19 patients from studies published between June 2020 and March 2021. This review was reported in line with the Preferred Reporting of Systematic Reviews and Meta-Analyses (PRISMA) extension for Scoping Reviews, and the protocol is registered with the Open Science Framework. Compared with our previously-published review of the period (December 2019–June 2020), the antibiotic prescribing rate for COVID-19 patients (June 2020–March 2021) was found to have declined overall (82.3% vs. 39.7%), for mild and moderate patients (75.1% vs. 15.5%), and for severe and critical patients (75.3% vs. 48.3%). The seven most frequently prescribed antibiotics in COVID-19 patients were all on the “Watch” list of the WHO AWaRe antibiotics classification. The overall reported bacterial infection rate in COVID-19 patients was 10.5%, and the most frequently reported resistant pathogen in COVID-19 patients was Staphylococcus aureus, followed by Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. There is an urgent need to establish comprehensive and consistent guidelines to assist clinicians in selecting appropriate antibiotics for COVID-19 patients when needed. The resistance data on the most frequently used antibiotics for COVID-19 patients for certain resistant pathogens should be closely monitored.
登录
查看更多内容
DOI：
10.1016/s2213-2600(21)00263-0
发表时间：
2021-10
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Hinks TSC;Cureton L;Knight R;Wang A;Cane JL;Barber VS;Black J;Dutton SJ;Melhorn J;Jabeen M;Moss P;Garlapati R;Baron T;Johnson G;Cantle F;Clarke D;Elkhodair S;Underwood J;Lasserson D;Pavord ID;Morgan S;Richards D
通讯作者：
Richards D
DOI：
10.1016/j.cmi.2020.07.016
发表时间：
2020-12
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Langford BJ;So M;Raybardhan S;Leung V;Westwood D;MacFadden DR;Soucy JR;Daneman N
通讯作者：
Daneman N
DOI：
10.3390/antibiotics11020276
发表时间：
2022-02-19
期刊：
Antibiotics (Basel, Switzerland)
影响因子：
--
作者：
Ahmed N;Khan M;Saleem W;Karobari MI;Mohamed RN;Heboyan A;Rabaan AA;Mutair AA;Alhumaid S;Alsadiq SA;Bueid AS;Santali EY;Alestad JH
通讯作者：
Alestad JH
DOI：
10.1016/s0140-6736(21)02724-0
发表时间：
2022-02-12
期刊：
Lancet (London, England)
影响因子：
--
作者：
Antimicrobial Resistance Collaborators
通讯作者：
Antimicrobial Resistance Collaborators
DOI：
10.3390/ijerph19074005
发表时间：
2022-03-28
影响因子：
--
作者：
Kamara IF;Kumar AMV;Maruta A;Fofanah BD;Njuguna CK;Shongwe S;Moses F;Tengbe SM;Kanu JS;Lakoh S;Mansaray AHD;Selvaraj K;Khogali M;Zachariah R
通讯作者：
Zachariah R